Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2026 | Clonal hematopoiesis & donor-derived leukemia: insights from an EHA-EBMT joint session

Ibrahim Yakoub-Agha • 12 Jun 2026
EHA 2026
General Leukemia

Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, briefly discusses the development of neoplasms in donor cells post-transplantation, noting that the recipient microenvironment can play a role in the development of leukemia. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ibrahim Yakoub-Agha

MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
2:41
MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
Ibrahim Yakoub-Agha • 12 Jun 2026
Should routine CH screening of donors become standard practice across transplant programs?
0:45
Should routine CH screening of donors become standard practice across transplant programs?
Ibrahim Yakoub-Agha • 13 Jun 2026
Considerations when screening donors for CH mutations to assess the risk of donor-derived leukemia
4:30
Considerations when screening donors for CH mutations to assess the risk of donor-derived leukemia
Ibrahim Yakoub-Agha • 13 Jun 2026
Linking poor cytogenetics and outcomes in MDS
2:04
Linking poor cytogenetics and outcomes in MDS
Ibrahim Yakoub-Agha • 12 Dec 2021

Related Videos

MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
2:41
MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
Ibrahim Yakoub-Agha • 12 Jun 2026
Insights into the real-world REVIVE study: venetoclax-based low-intensity therapy in AML
2:44
Insights into the real-world REVIVE study: venetoclax-based low-intensity therapy in AML
Yakir Moshe • 13 Jun 2026
Guidance for community oncologists navigating the AML treatment landscape
1:35
Guidance for community oncologists navigating the AML treatment landscape
Yakir Moshe • 13 Jun 2026
Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways
2:00
Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways
Maria Teresa Voso • 12 Jun 2026
The content of VJHemOnc is intended for healthcare professionals